JP2023523568A5 - - Google Patents
Info
- Publication number
- JP2023523568A5 JP2023523568A5 JP2022562528A JP2022562528A JP2023523568A5 JP 2023523568 A5 JP2023523568 A5 JP 2023523568A5 JP 2022562528 A JP2022562528 A JP 2022562528A JP 2022562528 A JP2022562528 A JP 2022562528A JP 2023523568 A5 JP2023523568 A5 JP 2023523568A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- subject
- level
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009400P | 2020-04-13 | 2020-04-13 | |
| US63/009,400 | 2020-04-13 | ||
| PCT/US2021/026816 WO2021211418A1 (en) | 2020-04-13 | 2021-04-12 | Methods for treating anemia using an actriib ligand trap and fedratinib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023523568A JP2023523568A (ja) | 2023-06-06 |
| JP2023523568A5 true JP2023523568A5 (cg-RX-API-DMAC7.html) | 2024-04-05 |
Family
ID=78085002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562528A Pending JP2023523568A (ja) | 2020-04-13 | 2021-04-12 | ActRIIBリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181690A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4135736A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023523568A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230003502A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115427056A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021256419A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022020628A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297258A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012610A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021211418A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| EP3227675B1 (en) * | 2014-12-03 | 2023-03-15 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
| CA2983440C (en) * | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| TWI814187B (zh) * | 2015-05-13 | 2023-09-01 | 美商西建公司 | 使用ACTRII配位體捕捉以治療β-地中海型貧血 |
| LT3490582T (lt) * | 2016-07-27 | 2024-07-25 | Acceleron Pharma Inc. | Kompozicijos, skirtos naudoti gydant mielofibrozę |
| US11202818B2 (en) * | 2016-09-14 | 2021-12-21 | President And Fellows Of Harvard College | Methods and compositions for modulating erythropoiesis |
| JOP20190085A1 (ar) * | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| WO2018231905A1 (en) * | 2017-06-14 | 2018-12-20 | Celgene Corporation | Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia |
| MX2021001985A (es) * | 2018-08-21 | 2021-04-28 | Sierra Oncology Inc | Metodos agnosticos de conteo de plaquetas para tratar la mielofibrosis. |
| MA53745A (fr) * | 2018-09-25 | 2021-08-04 | Impact Biomedicines Inc | Procédés de traitement de troubles myéloprolifératifs |
-
2021
- 2021-04-12 US US17/995,915 patent/US20230181690A1/en active Pending
- 2021-04-12 MX MX2022012610A patent/MX2022012610A/es unknown
- 2021-04-12 CN CN202180028593.0A patent/CN115427056A/zh active Pending
- 2021-04-12 IL IL297258A patent/IL297258A/en unknown
- 2021-04-12 KR KR1020227039230A patent/KR20230003502A/ko active Pending
- 2021-04-12 AU AU2021256419A patent/AU2021256419A1/en active Pending
- 2021-04-12 JP JP2022562528A patent/JP2023523568A/ja active Pending
- 2021-04-12 EP EP21787716.6A patent/EP4135736A4/en active Pending
- 2021-04-12 WO PCT/US2021/026816 patent/WO2021211418A1/en not_active Ceased
- 2021-04-12 BR BR112022020628A patent/BR112022020628A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7342167B2 (ja) | 腫瘍を治療するための抗b7-h1抗体 | |
| AU2005240082B2 (en) | Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients | |
| JP2020524139A5 (cg-RX-API-DMAC7.html) | ||
| TWI877239B (zh) | 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法 | |
| JP2016505240A5 (cg-RX-API-DMAC7.html) | ||
| CN109661241A (zh) | 使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法 | |
| JP2019206562A (ja) | 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 | |
| TW201712035A (zh) | 基於過敏反應素-1拮抗劑之癌免疫增強劑 | |
| JP2023526590A5 (cg-RX-API-DMAC7.html) | ||
| JPH10510553A (ja) | 多外傷後の多発性臓器不全の防止のための及び体外血液循環後の急性臓器損傷の防止のための抗−セレクチン抗体 | |
| EP4736884A1 (en) | Treatment combination, and use thereof and treatment method | |
| CN111533782A (zh) | 一种靶向免疫检查点lag-3的活性多肽及其应用 | |
| US20240368271A1 (en) | Targeting GPR65 for the Treatment of Cancer in Overweight and Obese Individuals | |
| WO2018209017A1 (en) | Cancer treatment with a cxcl12 signaling inhibitor and an immune checkpoint inhibitor | |
| CN113117072A (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
| US20240150469A1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| WO2024037594A1 (en) | Combination treatment with orelabrutinib and tafasitamab | |
| EP3008089A1 (en) | Combination of cd37 antibodies with chlorambucil | |
| WO2025067383A1 (zh) | 用TACI-Fc融合蛋白治疗抗体介导性排斥反应的方法 | |
| CN102614180A (zh) | 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用 | |
| US11324774B2 (en) | Compositions of oral alkaline salts and metabolic acid inducers and uses thereof | |
| RU2802962C2 (ru) | Композиции и способы лечения рака печени | |
| CN121693348A (zh) | 肿瘤联合治疗及使用方法 | |
| HK40102408B (en) | Pharmaceutical composition containing anti-lag-3 antibody and application thereof | |
| WO2025052354A1 (en) | Syk inhibitors for use in the treatment of immune checkpoint inhibition induced adverse events |